Lv1
40 积分 2025-05-19 加入
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
5个月前
已完结
GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies
7个月前
已完结
Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors
7个月前
已完结
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
7个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
7个月前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
7个月前
已完结
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
7个月前
已完结
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis
7个月前
已完结
The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario
7个月前
已完结
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
7个月前
已完结
皖公网安备34019202002308
